CVM Quote, Financials, Valuation and Earnings

IGC Pharma has a net margin of -- compared to CEL-SCI's net margin of -711.67%. CEL-SCI's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 2654.82%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1195.55%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.948%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. CEL-SCI's net income of -$7.1M is lower than IGC Pharma's net income of -$1.8M. Notably, CEL-SCI's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 17.59x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to CEL-SCI's net margin of -49.65%. CEL-SCI's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 2654.82%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that CEL-SCI has higher upside potential than NovaBay Pharmaceuticals, analysts believe CEL-SCI is more attractive than NovaBay Pharmaceuticals.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. CEL-SCI's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

OS Therapies has a net margin of -- compared to CEL-SCI's net margin of --. CEL-SCI's return on equity of -- beat OS Therapies's return on equity of --.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 2654.82%. On the other hand OS Therapies has an analysts' consensus of $13.50 which suggests that it could grow by 743.75%. Given that CEL-SCI has higher upside potential than OS Therapies, analysts believe CEL-SCI is more attractive than OS Therapies.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison OS Therapies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OS Therapies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. OS Therapies pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than OS Therapies quarterly revenues of --. CEL-SCI's net income of -$7.1M is lower than OS Therapies's net income of -$2.9M. Notably, CEL-SCI's price-to-earnings ratio is -- while OS Therapies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus -- for OS Therapies. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to CEL-SCI's net margin of 35.65%. CEL-SCI's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 2654.82%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 408.77%. Given that CEL-SCI has higher upside potential than Protalix BioTherapeutics, analysts believe CEL-SCI is more attractive than Protalix BioTherapeutics.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. CEL-SCI's net income of -$7.1M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, CEL-SCI's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 95.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 4.43x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.